My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Future Enterprises standalone net profit rises 615.37% in the June 2016 quarter

Sep 14,2016

Net profit of Future Enterprises rose 615.37% to Rs 315.48 crore in the quarter ended June 2016 as against Rs 44.10 crore during the previous quarter ended June 2015. Sales declined 67.64% to Rs 921.19 crore in the quarter ended June 2016 as against Rs 2846.84 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales921.192846.84-68
OPM %24.969.91-
PBDT295.07184.1360
PBT142.3249.92185
NP315.4844.10615

Powered by Capital Market - Live News

Suven Life Sciences gains after securing product patent in Australia
Jan 23,2017

The announcement was made during trading hours today, 23 January 2017.

Meanwhile, the BSE Sensex was up 41.68 points, or 0.15%, to 27,076.18.

On the BSE, so far 38,000 shares were traded in the counter, compared with average daily volumes of 56,949 shares in the past one quarter. The stock had hit a high of Rs 178.40 and a low of Rs 170.70 so far during the day.

The stock hit a 52-week high of Rs 228.50 on 30 May 2016. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had underperformed the market over the past 30 days till 20 January 2017, rising 2.62% compared with the 4.06% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 14.49% as against Sensexs 3.71% decline.

The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.

Suven Life Sciences announced that the grant of one product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and the patent is valid through 2033.

The granted claims of the patents are from the mechanism of action include the class of selective 5HT4 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers disease, Attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

With these new patents, Suven has a total of twenty five (25) granted patents from Australia. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Sciences net profit rose 5.2% to Rs 26.56 crore on 1.2% decline in net sales to Rs 115.55 crore in Q2 September 2016 over Q2 September 2015.

Suven Life Science is a bio-pharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.

Powered by Capital Market - Live News

Suzlon Energy secured repeat order of 50.40 MW
Jan 23,2017

Suzlon Energy announced its repeat order win of 50.40 MW from a leading power utility. The project consists of 24 units of S97 120 m hybrid tower with rated capacity of 2.1 MW. Located in Kutch, Gujarat, the project will be completed by March 2017.

Powered by Capital Market - Live News

Suzlon Energy secured repeat order of 50.40 MW
Jan 23,2017

Suzlon Energy announced its repeat order win of 50.40 MW from a leading power utility. The project consists of 24 units of S97 120 m hybrid tower with rated capacity of 2.1 MW. Located in Kutch, Gujarat, the project will be completed by March 2017.

Powered by Capital Market - Live News

Citadel Realty & Developers to consider December quarter results
Jan 23,2017

Citadel Realty & Developers announced that a Meeting of Board of Directors of the Company is scheduled to be held on 30 January 2017, inter alia, to take on record the Un-audited Financial Results, for the year (F. Y. 2016 - 2017) ended on 31 December 2016.

Powered by Capital Market - Live News

Board of Hem Holdings & Trading to consider December quarter results
Jan 23,2017

Hem Holdings & Trading announced that a Meeting of the Board of Directors of the Company will be held on 10 February 2017 to consider and adopt Un-Audited Financial Results (Standalone and Consolidated) for the quarter ended on 31 December 2016.

Powered by Capital Market - Live News

D-Link India jumps after strong Q3 numbers
Jan 23,2017

The result was announced on Saturday, 21 January 2017.

Meanwhile, the BSE Sensex was up 97.71 points, or 0.36%, to 27,132.21.

On the BSE, so far 1.76 lakh shares were traded in the counter, compared with average daily volumes of 1.33 lakh shares in the past one quarter. The stock had hit a high of Rs 123.90 and a low of Rs 117.50 so far during the day.

The stock hit a 52-week high of Rs 145.50 on 19 February 2016. The stock hit a 52-week low of Rs 75.25 on 21 September 2016. The stock had outperformed the market over the past 30 days till 20 January 2017, rising 4.78% compared with the 4.06% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 22.86% as against Sensexs 3.71% decline.

The small-cap company has equity capital of Rs 7.10 crore. Face value per share is Rs 2.

D-Link India is engaged in the design, manufacture and marketing of advanced networking, broadband, digital, voice and data communications solutions.

Powered by Capital Market - Live News

Unichem Lab moves higher after good Q3 outcome
Jan 23,2017

The result was announced on Saturday, 21 January 2017.

Meanwhile, the S&P BSE Sensex was up 102.10 points or 0.38% at 27,136.60.

On the BSE, 6,713 shares were traded on the counter so far as against the average daily volumes of 12,805 shares in the past one quarter. The stock had hit a high of Rs 279 and a low of Rs 273 so far during the day.

The stock had hit a 52-week high of Rs 319.90 on 20 October 2016 and a 52-week low of Rs 189 on 11 February 2016. The stock had underperformed the market over the past one month till 20 January 2017, advancing 0.65% compared with the Sensexs 2.76% rise. The scrip had also underperformed the market over the past one quarter, declining 11.52% as against the Sensexs 3.89% fall.

The small-cap company has equity capital of Rs 18.17 crore. Face value per share is Rs 2.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex APIs as well as dosage forms.

Powered by Capital Market - Live News

Agenda for board meeting of Himalya International
Jan 23,2017

Himalya International announced that the Board of Directors will meet on 28 January 2017 to consider and approved the following -

To consider unaudited financial results for the quarter ended 31 December 2016.

To consider progress and further steps to be taken for the assets reconstruction plan under the company scheme of demerger.

To review pending export orders and further development of products for exports as per customers requirements.

To consider revival of marketing all products within the country and discuss the strategy to review Himalya Fresh Brand for all Companys products.

Powered by Capital Market - Live News

Board of Divis Laboratories to consider Q3 results
Jan 23,2017

Divis Laboratories announced that a meeting of Board of Directors of the Company is scheduled to be held on 04 February 2017, inter alia, to consider and approve, the un-audited financial results for the quarter and nine months ended 31 December 2016(Q3).

Powered by Capital Market - Live News

Bharat Petroleum Corporation to consider Q3 results
Jan 23,2017

Bharat Petroleum Corporation announced that a meeting of the Board of Directors of the Company will be held on 09 February 2017, inter alia, to take on record the Unaudited financial Results (Provisional) of the Company for the quarter ended 31 December 2016(Q3).

Powered by Capital Market - Live News

3M India to consider Q3 and 9M results
Jan 23,2017

3M India announced that a meeting of the Board of Directors will be held on 09 February 2016, inter alia, to consider and approve the unaudited financial results for the quarter and nine months ended 31 December 2016.

Powered by Capital Market - Live News

Dilip Buildcon gains after winning contract
Jan 23,2017

The announcement was made after market hours on Friday, 20 January 2017.

Meanwhile, the BSE Sensex was up 106.31 points, or 0.39%, to 27,140.81.

On the BSE, so far 3,665 shares were traded in the counter, compared with average daily volumes of 27,772 shares in the past one quarter. The stock had hit a high of Rs 241.15 and a low of Rs 238.10 so far during the day.

The stock hit a record high of Rs 261.90 on 1 December 2016. The stock hit a record low of Rs 178.60 on 9 November 2016. The stock had outperformed the market over the past 30 days till 20 January 2017, rising 7.49% compared with the 4.06% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 4.56% as against Sensexs 3.71% decline.

The mid-cap company has equity capital of Rs 136.77 crore. Face value per share is Rs 10.

Dilip Buildcon (DBL) said its joint venture (JV) firm, DBL-DECO, received letter of award (LoA) from Northem Coalfields (NCL) (Madhya Pradesh) for excavation of overburden of first dig (solid) and re-handling by mechanical means at specified places at Nigahi OCP of NCL at a project cost of Rs 1673.58 crore, having a weighted average lead 5.68 kilometers and estimated quantity of 13,24,60,000 BCM.

Net profit of Dilip Buildcon declined 82.7% to Rs 6.97 crore on 3.5% rise in net sales to Rs 915.66 crore in Q2 September 2016 over Q2 September 2015.

Dilip Buildcon is a road-focused engineering procurement construction (EPC) contractor. The company develops infrastructure across the country in diverse areas such as roads & bridges, water sanitation & sewage, irrigation, industrial, commercial & residential buildings.

Powered by Capital Market - Live News

Kalpataru Power gains after securing new orders
Jan 23,2017

The announcement was made after market hours on Friday, 20 January 2017.

Meanwhile, the S&P BSE Sensex was down 39.53 points or 0.15% at 26,994.97.

On the BSE, 8,252 shares were traded on the counter so far as against the average daily volumes of 10,205 shares in the past one quarter. The stock had hit a high of Rs 276 and a low of Rs 269.40 so far during the day.

The stock had hit a 52-week high of Rs 286.55 on 30 August 2016 and a 52-week low of Rs 160 on 12 February 2016. The stock had outperformed the market over the past one month till 20 January 2017, advancing 11.74% compared with the Sensexs 2.76% rise. The scrip had also outperformed the market over the past one quarter gaining 3.9% as against the Sensexs 3.89% fall.

The mid-cap company has equity capital of Rs 30.69 crore. Face value per share is Rs 2.

Kalpataru Power Transmission (KPTL) said that it has secured new orders exceeding Rs 825 crore.

The contracts include various transmission projects in Africa and CIS region of about Rs 440 crore, two pipeline project from Indian Oil Corporation and GAIL (India) of about Rs 277 crore and the railway project by CORE of about Rs 110 crore.

Commenting on the new order announcements, Manish Mohnot, Managing Director, KPTL said, the company continued to receive repeat orders from Africa region and has built a reasonable order book for its pipeline and railway business. It expects to close the year with a healthy order book.

Kalpataru Power Transmissions net profit rose 21.7% to Rs 57.81 crore on 19.5% rise in net sales to Rs 1,101.21 crore in Q2 September 2016 over Q2 September 2015.

Kalpataru Power Transmission is an engineering, procurement and construction (EPC) contracting company with a diversified portfolio in power transmission & distribution, cross country pipeline, oil & gas field surface facilities, civil infrastructure projects, power generation (biomass) as well as railway projects.

Powered by Capital Market - Live News

Ruchi Soya drops on profit booking
Jan 23,2017

Meanwhile, the S&P BSE Sensex was up 93.48 points or 0.35% at 27,127.98.

On the BSE, 6.59 lakh shares were traded on the counter so far as against the average daily volumes of 1.66 lakh shares in the past one quarter. The stock had hit a high of Rs 29.20 and a low of Rs 26 so far during the day.

The stock had hit a 52-week high of Rs 33.20 on 28 March 2016 and a 52-week low of Rs 17.75 on 25 May 2016. The stock had outperformed the market over the past one month till 20 January 2017, advancing 43.08% compared with the Sensexs 2.76% rise. The scrip had also outperformed the market over the past one quarter gaining 15.86% as against the Sensexs 3.89% fall.

The small-cap company has equity capital of Rs 66.82 crore. Face value per share is Rs 2.

Shares of Ruchi Soya Industries (Ruchi Soya) had rallied 36.65% in two trading sessions to settle at Rs 27.40 on Friday, 20 January 2017, from its close of Rs 20.05 on 18 January 2017. The rally was fueled by media reports that the company is expected to enter into a marketing deal with Baba Ramdev promoted Patanjali Ayurved.

Media reports suggested that Patanjali will start branding and marketing the edible oil produced by Ruchi Soya across its 13 facilities, which will ensure guaranteed sales to Ruchi Soya as well as cut its distribution and marketing costs.

However, Ruchi Soya, before market hours today, 23 January 2017, in a clarification issued to the stock exchanges, said that it has no intention of diluting (or cobranding) its brands, sales and distribution network as reported in the media news article. However, in the ordinary course of business, the company explores opportunities to enter into business arrangements for third party manufacturing or job processing to optimize capacity utilisation of production facilities for the benefit of the stakeholders.

Ruchi Soya Industries net profit fell 77.92% to Rs 26.75 crore on 9.5% decline in net sales to Rs 4846.07 crore in Q2 September 2016 over Q2 September 2015.

Ruchi Soya Industries is a leading manufacturer and marketer of edible oils, soya food, premium table spread, vanaspati and bakery fats.

Powered by Capital Market - Live News

Lupin to announce Q3 results
Jan 23,2017

Lupin announced that a meeting of the Board of Directors of the Company will be held on 09 February 2017, inter alia, to consider and take on record the unaudited financial results for the quarter ended 31 December 2016 (Q3).

Powered by Capital Market - Live News